Novel Drug Delivery Strategies for the Treatment of Onychomycosis
-
Published:2019-05-10
Issue:1
Volume:7
Page:24-38
-
ISSN:2211-7385
-
Container-title:Pharmaceutical Nanotechnology
-
language:en
-
Short-container-title:PNT
Author:
Dhamoon Rupinder K.1, Popli Harvinder1, Gupta Madhu1
Affiliation:
1. Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Pushp Vihar, Sector-3, M.B Road, New Delhi -110017, India
Abstract
Onychomycosis accounts for 50% of all nail disease cases and is commonly
caused by dermatophytes. It was primarily considered a cosmetic problem
but has been garnering attention lately due to its persistent nature and difficult
treatment with relapses. With prolonged treatment duration and high cost involved
in treating onychomycosis, several attempts have been made in overcoming the
rigid nail barrier. The conventional treatment of onychomycosis involves oral and
topical therapy. The oral antifungal agents though quite effective, are hepato-toxic
and cause drug-drug interactions. Topical therapy is more patient compliant being
devoid of such adverse effects but it suffers from another setback of improper nail
penetration. Amorolfine and ciclopirox nail lacquers are popular market products.
Since decades, efforts have been made to enhance topical delivery for efficiently
treating onychomycosis. Mechanical, physical and chemical methods have been
employed. Despite all the attempts made, the nail delivery issues are far from being
solved. Recently, the focus has shifted to novel drug delivery systems like nanoparticles,
microemulsions, polymeric films and nail lacquers for enhanced drug
permeation and localized therapy. The research around the world is exploring their
potential as effective treatment options. This review intends to further explore the
novel delivery strategies to treat a persistent fungal infection like onychomycosis.
Publisher
Bentham Science Publishers Ltd.
Subject
Biomedical Engineering,Pharmaceutical Science
Reference80 articles.
1. Thapa RK, Choi JY, Go TG. Arch Pharm Res, Development of ciclopirox nail lacquer with enhanced permeation and retention.,, 2016, 39,, 953-959, 2. McAuley WJ, Jones SA, Traynor MJ, Guesné S, Murdan S, Brown MB. Eur J Pharm Biopharm, An investigation of how fungal infection influences drug penetration through onychomycosis patient’s nail plates.,, 2016, 102,, 178-184, 3. Adekhandi S, Pal S, Sharma N, Juyal D. Cutis, Incidence and epidemiology of onychomycosis in patients visiting a tertiary care hospital in India.,, 2015, 95,, E20-E5, 4. Ghannoum M, Isham N. PLoS Pathog, Fungal nail infections [onychomycosis]: a never-ending story?,, 2014, 10,, e1004105-, 5. Kushwaha A, Murthy RN, Murthy SN, Elkeeb R, Hui X, Maibach HI. Drug Dev Ind Pharm, Emerging therapies for the treatment of ungual onychomycosis.,, 2015, 41,, 1-7,
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|